Colloidal silver for lung disease in cystic fibrosis

Journal of the Royal Society of Medicine, Supplement

Volumn 101, Issue SUPPL. 1, 2008, Pages

  Baral, V R ^a   Dewar, A L ^a   Connett, Gary J ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; COLISTIN; DORNASE ALFA; SILVER CHLORIDE; STEROID;

BACTERIUM CULTURE; BRONCHIECTASIS; BRONCHOSCOPY; BURKHOLDERIA; CASE REPORT; CONFERENCE PAPER; CONVALESCENCE; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DISEASE; LUNG FUNCTION; MALE; PSEUDOMONAS AERUGINOSA; SCHOOL CHILD; SPIROMETRY; STENOTROPHOMONAS MALTOPHILIA;

ANTI-BACTERIAL AGENTS; CHILD; COLLOIDS; COMPLEMENTARY THERAPIES; CYSTIC FIBROSIS; FORCED EXPIRATORY VOLUME; HUMANS; MALE; SILVER COMPOUNDS; TREATMENT OUTCOME;

EID: 49449105897     PISSN: 02675331     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.2008.s18012     Document Type: Conference Paper

References (5)

1. Westhofen M, Schafer H. Generalised argyrosis in man: neurological, ultra structural and x-ray micro analytical findings. Arch Otorhinolaryngol 1986;24:260-4
2. Lansdown AB. Critical observations on the neurotoxicity of silver. Crit Rev Toxicol 2007;37:237-50
3. Baker CD, Federico MJ, Accurso FJ. Skin discoloration following administration of colloidal silver in cystic fibrosis. Curr Opin Pedatr 2007;19:733-5
4. Bjarnsholt T, Kirketerp-Moller K, Kristiansen S, et al. Silver against Pseudomonas aeruginosa biofilms. APMIS 2007;115:921-8
5. Cannon CL, Capps GH, Hogue L, et al. A07: A murine model of Burkholderia dolosa pulmonary infection and treatment with a nebulised silver carbene compound. Abstracts of the International Burkholderia cepacia Working Group Meeting April 2005; Oklahoma, USA. http://www.go.to/cepacia